Disease · MONDO_0005395

movement disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. movement disorder. Diseases, record MONDO_0005395. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005395

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: movement disorder; Open Targets
Open Targets ID: MONDO_0005395; Open Targets
Other names: Abnormality of movement, Unusual movement, movement disease, movement disorders, tardive dyskinesia; Open Targets
Disease Ontology: DOID:480; Disease Ontology
MeSH: D009069; MeSH
NCI Thesaurus: C116757; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 18 drugs, from DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs18

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DEUTETRABENAZINE	CHEMBL3137326	Small molecule	Approval	EMA Human Drugs and TTD	5	3	3	Drugs and targets
VALBENAZINE TOSYLATE	CHEMBL3707248	Small molecule	Approval	DailyMed, FDA and TTD	5	0	0	Drugs and targets
IOFLUPANE I 123	CHEMBL3989517	Small molecule	Approval	DailyMed and EMA Human Drugs	3	0	0	Drugs and targets
PENICILLAMINE	CHEMBL1430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
TRIENTINE HYDROCHLORIDE	CHEMBL3989777	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ZINC ACETATE	CHEMBL3184986	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
VALBENAZINE	CHEMBL2364639	Small molecule	Phase 3	ClinicalTrials.gov and TTD	11	10	10	Drugs and targets
SARIZOTAN	CHEMBL220808	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PYRIDOXINE	CHEMBL1364	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 18

See all 18 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC18A2	Synaptic vesicular amine transporter	4	Synaptic vesicular amine transporter inhibitor	Approval	https://conductscience.org/library/genes/6571	Drugs and targets
DRD2	D(2) dopamine receptor	2	Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D(3) dopamine receptor	2	Dopamine D3 receptor agonist	Phase 3	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D(4) dopamine receptor	2	Dopamine D4 receptor agonist	Phase 3	https://conductscience.org/library/genes/1815	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	2	Serotonin 1a (5-HT1a) receptor agonist	Phase 3	https://conductscience.org/library/genes/3350	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/154	Drugs and targets
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	1	Voltage-gated N-type calcium channel alpha-1B subunit blocker	Phase 3	https://conductscience.org/library/genes/774	Drugs and targets
MTNR1A	Melatonin receptor	1	Melatonin receptor agonist	Unknown	https://conductscience.org/library/genes/4543	Drugs and targets
MTNR1B	Melatonin receptor	1	Melatonin receptor agonist	Unknown	https://conductscience.org/library/genes/4544	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00105508	Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia	Phase 3	506	2018-07-26	Parkinson's Disease, Dyskinesia	SARIZOTAN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00105521	Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia	Phase 3	398	2018-04-02	Parkinson's Disease, Dyskinesia	SARIZOTAN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02198794	Reducing Involuntary Movements in Participants With Tardive Dyskinesia	Phase 3	343	2021-03-01	Tardive Dyskinesia	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02291861	Addressing Involuntary Movements in Tardive Dyskinesia	Phase 3	298	2018-04-11	Tardive Dyskinesia	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT03176771	Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia	Phase 2/3	256	2023-08-14	Tardive Dyskinesia	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02274558	A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3	234	2017-07-11	Tardive Dyskinesia	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02405091	Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Phase 3	167	2018-11-30	Tardive Dyskinesia	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02736955	Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia	Phase 3	161	2018-12-19	Tardive Dyskinesia	VALBENAZINE	Its record names the disease	ClinicalTrials.gov
NCT02195700	Aim to Reduce Movements in Tardive Dyskinesia	Phase 2/3	117	2018-03-20	Tardive Dyskinesia	DEUTETRABENAZINE	Its record names the disease	ClinicalTrials.gov
NCT01688037	NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)	Phase 2	109	2017-11-08	Tardive Dyskinesia	VALBENAZINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Sarizotan vs Placebo: serious adverse events	23 of 252	25 of 252	504	NCT00105508	Trial comparisons
Part A and Part B Participants vs Part C: SD-809: deaths from any cause	8 of 337	2 of 80	417	NCT02198794	Trial comparisons
Part A and Part B Participants vs Part C: SD-809: serious adverse events	68 of 337	5 of 80	417	NCT02198794	Trial comparisons
SD-809 vs Placebo: deaths from any cause	0 of 58	0 of 59	117	NCT02195700	Trial comparisons
SD-809 vs Placebo: serious adverse events	3 of 58	5 of 59	117	NCT02195700	Trial comparisons
Valbenazine vs Placebo: deaths from any cause	0 of 51	1 of 49	100	NCT01733121	Trial comparisons
Valbenazine vs Placebo: serious adverse events	0 of 51	2 of 49	100	NCT01733121	Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36114799	RESULT	1	PubMed
28668671	RESULT	1	PubMed
18175337	RESULT	1	PubMed
40265997	DERIVED	2	PubMed
39186921	DERIVED	1	PubMed
38557959	DERIVED	3	PubMed
38421921	DERIVED	1	PubMed
32419679	DERIVED	1	PubMed
31617235	DERIVED	4	PubMed
31296586	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005395

GET https://conductscience.org/api/diseases/v1/MONDO_0005395/trials?page=2

API reference For AI assistants